Uwell Biopharma, Inc. (TPEX:7902)

Taiwan · Delayed Price · Currency is TWD

24.35

-3.50 (-12.57%)

At close: Nov 6, 2026

Market Cap	4.88B
Revenue (ttm)	35.00K -92.2%
Net Income	-71.61M
EPS	-0.37
Shares Out	200.61M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	392,215
Open	26.80
Previous Close	27.85
Day's Range	22.80 - 26.90
52-Week Range	7.80 - 51.50
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Uwell Biopharma

Uwell Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel cancer immunotherapeutic in Taiwan. The company provides chimeric antigen receptor T-cell (CAR-T) therapy platforms, lentiviral vector production, and related services. The company was founded in 2020 and is based in New Taipei City, Taiwan. [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2020

Country Taiwan

Stock Exchange Taipei Exchange

Ticker Symbol 7902

Full Company Profile

Financial Performance

In 2025, Uwell Biopharma's revenue was 35,000, a decrease of -92.22% compared to the previous year's 450,000. Losses were -66.20 million, 62.0% more than in 2024.

Financial Statements